



PATENTS

Attorney Docket No. 25846-0003

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the US Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington DC 20231, on June 11, 2001.

verek P. Freyberg, Reg. No. 29,250

b/11/01 Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Elfi Biedermann et al.

App. No.: 09/693,558 : Art Unit: (not yet known)

Filed: October 20, 2000 : Examiner: (not yet known)

For: Use of vitamin PP compounds

Commissioner for Patents Washington, DC 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant directs the attention of the Office to the documents listed on the attached Form PTO-1449, which may be relevant to the examination of this application.

Documents A4 through A6 were cited in the International Search Report issuing on the PCT application of which this application is a continuation, where they were cited as "A" (technical background) documents.

No English-language versions of documents A3 or A4 are known to Applicants. Document A3 appears to describe dragee and injectable forms of the anticancer drug cyclophosphamide.

Document A4 contains its own English-language abstract, and a Chemical Abstracts abstract is given as document A1. Only the erratum sheet of document A6 was cited in the ISR.

Application No.: 09/693,558 Page 2

No representation is made by this Information Disclosure Statement that a search has been made; or that the information disclosed is, or is considered to be, material to patentability under 37 CFR 1.56(b).

Respectfully submitted,

Derek P. Freyberg

Attorney for Applicants

Reg. No. 29,250

Heller Ehrman White & McAuliffe LLP 275 Middlefield Road Menlo Park, California 94025-3506 (650) 324-7014

June 11, 2001

PATENTS

Attorney Docket No. 25846-0003

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the US Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington DC 20231, on June 11, 2001

Derek P. Freyberg, Red. No. 29,250

<u>///01</u> Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Elfi Biedermann et al.

App. No.: 09/693,558 : Art Unit: (not yet known)

Filed: October 20, 2000 : Examiner: (not yet known)

For: Use of vitamin PP compounds

Commissioner for Patents Washington, D.C. 20231

Sir:

PERFECTION OF PRIORITY CLAIM

In perfection of the claim to foreign priority under 35 USC 119(a)-(d) for this application, enclosed please find a copy of German Patent Application No. 198 18 044.6, filed April 22, 1998.

Respectfully submitted,

Derek P. Freyberg

Attorney for Applicants Registration No. 29,250

Heller Ehrman White & McAuliffe LLP 275 Middlefield Road Menlo Park, California 94025-3506 (650) 324-7014 June 11, 2001



INFORMATION DISCLOSURE STATEMENT

(37 CFR 1.56, 1.97, and 1.98)

SHEET 1 OF 1

ATTORNEY DOCKET		APPLICATION NO.			
	25846-0003	09/693,558			
	APPLICANT(S)	·			
	Elfi Biedermann, et al.				
	FILING DATE	GROUP			

					October 20, 2000	16	1614			
US PATENT DOCUMENTS										
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME CLASS/ SUBCLASS		FILING DATE (If appropriate)				
FOREIGN PATENT DOCUMENTS										
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY		TRANSLATION (YES/NO)				
OTHER DOCUMENTS										
† EX'R *										
INITIAL	REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)								
PS	A1 Chem. Abstr. 115: 150041w (1991): abstract of Shneider, Patol. Fiziol. Eksp. Ter., 1991(1), 9-10.						(1), 9-10.			
B	A2	Chem. Abstr. 124: 1/73015r (1996): abstract of Caraher et al., Biochem. Soc. Trans., 24(1), 725 (1996).								
1/3	А3	Rote List 1997, ECV Editio Cantor. Item 86 013 Cyclostin Dragees/Cyclostin Trockensubstanz								
	Α4	A.B. Schneider, "Antiischemic heart protection with thiamine and nicotinamide", <i>Patol. Fiziol. Exp. Ter.</i> , 1991(1), 9-10-								
B	A5 L.K. Klaidman et al., "Nicotinamide as a precursor for NAD+ prevents apoptosis in the mouse brain induced by tertiary-butyl hydroperoxide", Neuroscience Lett., 206, 5-8 (1996).									
1	A6	P. Pozzilli et al., "Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes", Eur. J. Endocrinol., 137, 558 (1997) Erratum.								

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant*.

DATE CONSIDERED

EXAMINER'S SIGNATURE

^{*} If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 USC 120. 37 CFR 1.98(d).